3 Produkte am Markt -- 4 Zulassungsanträge bei der FDA eingereicht . Erste FDA-Entscheidung am 30 November .. Niedrig bewertete Aktie mit massiv upside potential .


Aquestive Therapeutics (AQST)

Marktkap $80 Million
Cash: $22 Million
Kurs: $3.20


Präsentation
http://investors.aquestive.com/stati...8-b6008edb43a6


Insiderkäufe
http://openinsider.com/search?q=aqst



Bevorstehende milestones für das 4Q:

FDA Entscheidung für Exservan (ALS drug) am 30.November

PoC daten (Acromegaly) im 4Q

US Zulassungsantrag für Libervant im 4Q

NDA resubmission Parkinson drug im 4Q



https://nctynews.com/wedbush-reaffir...cs-nasdaqaqst/

NASDAQ:AQST)‘s stock had its “buy” rating restated by equities research analysts at Wedbush in a research report issued to clients and investors on Wednesday, AnalystRatings.com reports. They presently have a $34.00 price objective on the stock.


Größten Aktionäre

Crestline ...11.5M
Perceptive ...2.1M
Monosol ...1.9M
Schobel ...1.1M
Kendall (Keith J.) ...729.2K
Opaleye ...590.0K
MFS Investment ...473.3K
BlackRock ...378.3K
Bratton (Douglas K) ...335.0K
The Vanguard ...312.1K

48630172-15670032396286216.png


https://static1.seekingalpha.com/upl...jpg?1568133486